Multistage Vectors (MSV) for Ovarian Cancer Therapeutics

用于卵巢癌治疗的多阶段载体 (MSV)

• 批准号: 7983095
• 负责人: Gabriel Lopez-Berestein
• 金额: $ 74.5万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7983095
• 关键词: Address; Albumins; Animals; Antineoplastic Agents; Apoptosis; Binding; Biocompatible; Cancer Biology; Cancer Etiology; Cause of Death; Cessation of life; Clinical; Complement; Data; Development; Diagnosis; Drug Delivery Systems; Drug Kinetics; FDA approved; Goals; Gold; Image; Legal patent; Liposomal Doxorubicin; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Micelles; Monitor; Nanotechnology; Neoplasm Metastasis; Ovarian Carcinoma; Paclitaxel; Patients; Pharmaceutical Preparations; Property; Proteome; Proteomics; Research Personnel; Silicic Acid; Silicon; Site; Small Interfering RNA; Solutions; Staging; Survival Rate; System; Technology; Therapeutic; Toxic effect; Treatment Efficacy; United States; Woman; Work; angiogenesis; base; cancer therapy; chemotherapy; clinically relevant; crosslink; improved; in vivo; inhibitor/antagonist; innovation; interest; meetings; nano; nanoimaging; nanoparticle; nanoscale; nanoshell; nanovector; novel; particle; response; response marker; small molecule; tool; tumor; tumor growth; vector

PROJECT TITLE: Mulfistage Vectors (MSV) for Ovarian Cancer Therapeufics PROJECT SUMMARY: Because ovarian cancer is fifth leading cause of cancer deaths in women and a leading cause of death from gynecologic cancers in the United States, it is necessary to develop novel therapeufic agents and strategies beyond convenfional chemotherapy for the treatment of advanced ovarian cancer. Nanotechnology meets this necessity because of the possibility to develop novel therapeufics. Project 1 alms to demonstrate the feasibility for translafion of a novel biocompatible nano-delivery system for efficient in vivo siRNA and drug delivery to achieve control of tumor growth and angiogenesis for a prolonged period. Project 1 will use the innovafive "multi-stage" approach, using biodegradable porous silicon particles as a carrier of therapeufic nanoparticles, which will offer a paradigm shift from convenfional nanotechnology based drug delivery by improving unfavorable pharmacokinefics of nanoparticles. Additionally, Project 1 aims to monitor therapeufic responses. Project 1 presents how novel nanotechnologies offer unequaled solufions to such undisputable necessity. The investigators will develop nanochip technologies to establish proteomic profiles to effectively monitor therapeufic responses and complement these with the development of sensifive gold-gold nanoshells to image tumor microvasculature with superb resolufion to monitor tumor vasculature response to therapy. Moreover, the investigators will utilize core-crosslinked polymeric micelles to detect and image active apoptosis in vivo, indicative of response to most anti-cancer therapies. The proposed work will greatly contribute to fill the existing gap between discovery of basic cancer biology and nanotechnology

项目名称：卵巢癌治疗的多阶段载体 (MSV) 项目摘要：因为卵巢癌是女性癌症死亡的第五大原因，也是女性癌症死亡的第五大原因。 妇科癌症是美国妇科癌症死亡的主要原因，因此有必要开发新的治疗方法 治疗晚期卵巢癌的常规化疗以外的治疗药物和策略 癌症。纳米技术满足了这一需求，因为它有可能开发出新的治疗方法。 项目 1 致力于证明新型生物相容性纳米递送系统的可行性 有效的体内 siRNA 和药物递送，以实现长期控制肿瘤生长和血管生成 时期。项目1将采用创新的“多阶段”方法，使用可生物降解的多孔硅颗粒 作为治疗性纳米颗粒的载体，这将带来传统纳米技术的范式转变 通过改善纳米颗粒的不利药代动力学来实现药物递送。此外，项目 1 的目标 监测治疗反应。项目 1 展示了新颖的纳米技术如何提供无与伦比的解决方案 如此无可争议的必要性。研究人员将开发纳米芯片技术来建立蛋白质组学 有效监测治疗反应并通过开发补充这些反应 灵敏的金-金纳米壳以卓越的分辨率对肿瘤微血管进行成像以监测肿瘤 脉管系统对治疗的反应。此外，研究人员将利用核心交联聚合物胶束 检测和成像体内活跃的细胞凋亡，表明对大多数抗癌疗法的反应。这 拟议的工作将极大地有助于填补基础癌症生物学的发现和 纳米技术